While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

Georgia’s father, a commercial pilot, is exposed to “thousands of people ... Nor is she allowed to buy the vaccine in B.C.

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

On Thursday, Moderna Inc. (NASDAQ:MRNA) reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 ...

US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease ...

Our primary commercial efforts remain dedicated to the largest ... give this vaccine candidate the highest probability of ...

utilized in an RSV re-vaccination setting and as part of a respiratory combination vaccine. Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the ...

A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to ...